Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

Pancreatic Cancer Clinical Trial

Official title:

A Randomized Controlled Phase II Study of Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02950025
• Other study ID #: 201611018
• Status: Terminated
• Phase: Phase 2
• Start date: January 19, 2017
• Est. completion date: March 19, 2018

Study information

• Verified date: March 2019
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In light of this new technology and preliminary findings of low toxicity of online, adaptive, magnetic resonance (M)-guided stereotactic radiation on a single arm prospective study, the investigators propose to compare this technique to online MR-guided stereotactic body radiation therapy (SBRT) without adaptation. Online plan adaptation increases treatment times for patients and comprises an increased burden on technical and clinical staff. Although preliminary trial results are encouraging, it remains unclear if the dosimetric benefits of online-adaptive planning studies will translate to measurable improvements in clinical outcomes that merit its routine use. In our preliminary study, plan adaptation was most often required when tumors were adjacent to the gastrointestinal tract (the esophagus to the sigmoid colon), as those structures were most commonly the dose-limiting structures and were noted to change in location on a day-to-day basis. For these reasons, abdominal disease sites have historically highlighted the limitations of SBRT. Specifically, the investigators will enroll patients with oligometastatic or unresectable primary disease of the non-liver abdomen to a randomized, prospective trial.

Patients will be randomized to one of two treatment arms, in which they will receive either online-adaptive, MRI-guided SBRT or non-adaptive MRI-guided SBRT. Both patient groups will undergo MRI simulation and MRI treatment localization with online MR monitoring and/or gating. All patients will be treated in five fractions over one to two weeks. By adhering to strict normal tissue constraints, the investigators expect toxicity to be within the current standard of care for the non-adaptive arm, with reduction in toxicity in the arm of patients who undergo adaptation based on daily anatomic changes.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: March 19, 2018
• Est. primary completion date: March 19, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Oligometastatic disease or unresectable primary abdominal malignancy with biopsy-proven primary disease histology of solid tumor categorization. Patients with a diagnosis of hepatocellular carcinoma do not require a biopsy.

• No more than three progressive sites of disease, with at least one of the disease sites to be deemed suitable for treatment with MRI-guided, online adaptive SBRT to the non-liver abdomen as per radiation oncology evaluation.

• Must be treated per protocol to lesion(s) of a single abdominal site that can reasonably be encompassed within a single treatment field. Treatment of additional site(s) outside of the abdomen while the patient is on trial is acceptable.

• The treated lesion must be within 2 cm of the abdominal gastrointestinal tract (abdominal esophagus to sigmoid colon) on the basis of cross sectional imaging study such as computed tomography (CT), positron emission tomography (PET)/CT, or MRI.

• Must be deemed medically fit for SBRT by the treating physician.

• At least 18 years of age.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Must have completed any systemic therapy at least one week prior to planned start of SBRT (two weeks preferred), and must have no plans to initiate systemic therapy for at least one week following end of SBRT (two weeks preferred).

• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

• Able to understand and willing to sign an Institutional Review Board (IRB) approved, written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

• Primary disease of hematologic origin, lymphoma, or small cell cancer.

• Past history of external beam radiotherapy within the projected treatment field of any of the disease sites to be treated by MRI-guided, online adaptive SBRT.

• Currently receiving any other investigational agents.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.

• Pregnant and/or breastfeeding. Patient must have a negative pregnancy test within 14 days of study entry.

• Medical contraindication to undergoing MR imaging.

Related Conditions & MeSH terms

• Cancer of the Pancreas
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma
• Pancreas Cancer
• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Device:
• Online, adaptive MR-guided SBRT
Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
• Online, non-adaptive MR-guided SBRT
Patients will not have online-adaptive treatment planning

Other:
• European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
30 questions 28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much 1 question asking about overall health with answers ranging from 1=very poor to 7 excellent 1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Grade 3 or Greater Toxicity Occurring in Patients Receiving Online, Adaptive, MRI-guided SBRT to the Abdomen and in Patients Receiving Non-adaptive SBRT	The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.; Grade 3 or higher toxicities that did not predate SBRT and are probably or definitely attributable to treatment; Please note that the following statistical analysis was not performed due to small sample size: Statistical analysis will be powered to detect a reduction of toxicity from 35% Grade 3 or greater toxicity to 10% Grade 3 or greater toxicity using online-adaptive therapy. Statistical analysis will be one-sided test for independent proportions.	Up through 6 months post-treatment (approximately 6 months and 2 weeks)
Secondary	Tumor Response Rate	Tumor response rate = rate of participants who have complete or partial response at the six month follow-up; Complete Response (CR): Disappearance of the target lesion. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.; Partial Response (PR): At least a 30% decrease in the (sum of the) diameter of the target lesion(s), taking as reference the baseline sum diameters.	At six month follow-up (approximately 6 months and 2 weeks)
Secondary	Progression-free Survival (PFS) Rate	PFS rate - the number of participants who have not progressed and/or died at the six-month follow-up; Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.; Please note that the planned statistical analysis wasn't able to be performed due to small sample size: Utilizing Kaplan-Meier methodology	At six month follow-up (approximately 6 months and 2 weeks)-up
Secondary	Disease Free Survival Rate	Disease free survival rate = the number of participants who are disease free (without any signs or symptoms of cancer) at the six-month follow-up; Please note that the planned statistical analysis wasn't able to be performed due to small sample size: Utilizing Kaplan-Meier methodology.	At six month follow-up (approximately 6 months and 2 weeks)
Secondary	Overall Survival (OS) Rate	Overall survival rate - number of participants alive at the six-month follow-up; Please note that the planned statistical analysis wasn't able to be performed due to small sample size: Utilizing Kaplan-Meier methodology.	At six month follow-up (approximately 6 months and 2 weeks)
Secondary	Patient Reported Overall Quality of Life During the Past Week as Measured by EORTC QLQ-C30 Quality of Life	Utilize both paired t-tests and repeated measures ANOVA to analyze QOL data (this was unable to be performed due to the small sample size); The question asked the participant "how would you rate your quality of life during the past week?"; The scale ranges from 1=very poor to 7 = excellent. The higher the score the better the quality of life.	Pre-treatment, six-weeks post treatment, and six months post-treatment
Secondary	Number of Participants With Local Failure		At six month follow-up (approximately 6 months and 2 weeks)

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine